Thiogenesis Therapeutics, Corp., 2026-06-09
An SEC Form D private-offering notice from Toronto, ON, Canada, a $28,964 filer-stated offering target in Biotech. Filed 2026-06-09. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Thiogenesis Therapeutics is a clinical-stage biotech developing sulfur-based thiol therapies, including lead candidate TTI-0102, to treat mitochondrial diseases such as MELAS and Leigh syndrome; it trades as TSXV: TTI and OTCQX: TTIPF.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Barricade Therapeutics Corp, 2026-06-10, Fort Worth, TX
- Conexeu Sciences Inc., 2026-06-10, $137K, Reno, NV
- Contraline, Inc., 2026-06-10, $115.9M, Charlottesville, VA
- Los Angeles Project Inc, 2026-06-08, $6.9M, Austin, TX
- HCW Biologics Inc., 2026-06-08, $4M, Miramar, FL
- Biostax Corp., 2026-06-08, $7.5M, Winter Park, FL
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.